BBM Clinical Integration
Considerations and Recommendations for Clinical Implementation of Blood-Based Biomarkers for Alzheimer’s Disease
Companion manuscripts published in Alzheimer's & Dementia
A Clear Roadmap for Effectively Integrating Blood Tests in Clinical Practice
Together, these publications represent a major step forward in diagnosing Alzheimer's disease, allowing for a more timely and accurate diagnostic experience for patients.
Several key barriers prevent integration of blood tests into clinical practice, such as a limited understanding of test characteristics, insufficient evidence on performance across diverse populations, and the ethical management of tests. The recommendations published identify actionable solutions to address these barriers and detail a framework for effective implementational pathways.
Several key barriers prevent integration of blood tests into clinical practice, such as a limited understanding of test characteristics, insufficient evidence on performance across diverse populations, and the ethical management of tests. The recommendations published identify actionable solutions to address these barriers and detail a framework for effective implementational pathways.
Key Takeaways from:
Triaging Implementation Pathway
This figure represents a simplified version of the pathway presented in the publication, “Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease,” illustrating where blood tests can be integrated as triaging tools to support the determination of eligibility for DMT.
Key Takeaways from:
Confirming Amyloid Pathology Implementation Pathway
This figure represents a simplified version of the pathway presented in the publication, “Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease,” illustrating where AD BBMs tests (red text) can be integrated as confirmatory tools to support the determination of eligibility for DMT.
Hear from Workgroup Co-Leads Chi Udeh-Momoh and Michelle Mielke on the Importance of Advancements in BBMs
Educational Resources For
Blood-Based Biomarkers
View Additional BBM Resources Here
Press & Media
Thank you to everyone who contributed to this effort:
- Michelle M. Mielke, Wake Forest University School of Medicine
- Matthew Anderson, Atrium Health
- J. Wesson Ashford, Stanford University School of Medicine
- Andreas Jeromine, ALZpath
- Pei-Jung Lin, Tufts Medical Center
- Allyson Rosen, Stanford University School of Medicine
- Jamie Tyrone, Patient Advocate
- Lawren VandeVrede, University of California, San Francisco
- Deanna Willis, Indiana University School of Medicine
- Oskar Hansson, Lund University
- Ara S. Khachaturian, Campaign to Prevent Alzheimer’s Disease
- Suzanne E. Schindler, Washington University School of Medicine
- Joan Weiss,, U.S. Department of Health & Human Services
- Richard Batrla, Eisai
- Sasha Bozeat, Roche
- John R. Dwyer, Global Alzheimer’s Platform Foundation
- Drew Holzapfel, Global CEO Initiative on Alzheimer’s Disease
- Daryl Rhys Jones, Eisai
- James F. Murray, Davos Alzheimer’s Collaborative
- Katherine A. Partrick, Global CEO Initiative on Alzheimer’s Disease
- Emily Scholler, Global CEO Initiative on Alzheimer’s Disease
- George Vradenburg, Global CEO Initiative on Alzheimer’s Disease
- Dylan Young, Guidehouse
- Joel B. Braunstein, C2N Diagnostics
- Samantha C. Burnham, Eli Lilly & Company
- Fabricio Ferreira de Oliveira, Federal University of São Paulo
- Yan Helen Hu, Eisai
- Soeren Mattke, University of Southern California
- Zul Merali, Brain and Mind Institute
- Mark Monane, C2N Diagnostics
- Marwan Noel Sabbagh, Barrow Neurological Institute
- Eli Shobin, Biogen
- Michael W. Weiner, University of California, San Francisco
- Chinedu T. Udeh-Momoh, Wake Forest University School of Medicine